Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
35% is GREAT. Do that every time and Kaboomski! Congrats.
Thank you. Now in your own words "Gooooooooooo ETRM!" - let's get it back on track today.
Yes, thanks. I'm still struggling trusting the buying on breakouts. I normally wait until after the breakout, and then when it falls back to the new support levels (old resistance) and go from there.
Am also in ACHN (3.31 at moment) at 3.36. Thoughts are its forming the cup and handle pattern on Daily and is working its way to the resistance in lower to mid 3.5's again (been there a few times) and hopefully makes its way up to the large gap above.
Short term gaps are also something to still learn more. The small gaps that appear after a mid-volume movement. As to whether enough volume was made so that it doesn't need to be filled, that's my dilemma.
I try for trades of 3 days to a few weeks or a month or two at the moment and lock in the profits of 10% or above. Has caused me to miss some other continuations where I could have doubled my % if held, (I got MSTX (15%), STEM (9%), AEZS (16%), etc., however they all went on further at the moment). But am trying hard to stick to my chart philosophy and follow Sheff's idealogy (and others) of LOCK IN PROFITS, LOCK IN PROFITS, LOCK IN PROFITS, and move along to the next one. As I get more confident, then maybe I'll leave a portion in the account for further gains. Thanks again.
SmurfVA, Thank you for your postings and rationale of the price, chart, and patterns that you think are in motion. The resistance and support levels are always interesting to hear (as well as stop loss levels). I can envision most myself, but nice to confirm it by reading what others think.
I appreciate your thoughts and am following along, comparing it to my interpretations. I've traded this 2x so far and both times did ok (10%) or more, so hoping 3rd time works as well. Am currently in at 2.31. I didn't completely follow my chart, used emotion, so bought higher then I wanted, but so far, am ok.
One of the things that I need to learn is that it's ok to buy a stock when its moving up - in breakout type of a mode, as long as there is volume and other catalysts pushing it.
Thanks again.
Craig Hallum Increases EnteroMedics Price Target to $6.00
Craig Hallum raised their price objective on shares of EnteroMedics (NASDAQ:ETRM) to $6.00 in a research note issued on Monday, Analyst Ratings.Net reports.
Craig Hallum’s price target would suggest a potential upside of 156.41% from the company’s current price.
link: http://www.wkrb13.com/markets/245138/craig-hallum-increases-enteromedics-price-target-to-6-00-etrm/
another link: http://www.streetinsider.com/Analyst+PT+Change/EnteroMedics+(ETRM)+PT+Raised+to+$6+at+Craig-Hallum/9025765.html
EnteroMedics is Favorite Idea for 2014 by Lake Street
January 3, 2014
In a report published Friday, Lake Street Capital Markets analyst Bruce Jackson rated EnteroMedics as the favorite idea for 2014.
Jackson reported that EnteroMedics is best positioned to benefit from several near-term trends. The analyst commented, “First, the current macro favors companies whose products address unmet treatment needs while making healthcare delivery more efficient and effective. Second, we see a continued improving environment for growth stocks and small-caps in 2014 as the Fed begins to taper and the yield curve should steepen. Third, small caps like ETRM should also continue to benefit from acquisition activity as large companies with strong balance sheets deploy cash in search of new growth.”
Lake Street anticipates that the company will shortly obtain an FDA panel date for the VBLOC obesity treatment device, which should take place at the end of the first quarter. In addition, Jackson noted that positive clinical data for new drugs, licensing deals, and potential M&A activity aided the healthcare sector in leading the broader market indices for all market cap segments in 2013. The analyst continued, commenting that investors are beginning to pursue higher-growth segments within Healthcare and specifically noted that Healthcare Information Technology moved up “in the anticipation of major changes being made to the healthcare payment systems in the United States.”
Link: http://www.benzinga.com/analyst-ratings/analyst-color/14/01/4191439/enteromedics-is-favorite-idea-for-2014-by-lake-street#ixzz2pU5Smq2f
Author Bio:
Bruce is a senior healthcare research analyst with more than twenty years of experience both on and off Wall Street. He focuses on companies poised to benefit from changes in the healthcare system and the drive for better patient outcomes at lower cost. In May, 2011, Bruce received an FT/StarMine Analyst Award for being the Number 1 stock picker in Health Care Equipment and Supplies and was named a Wall Street Journal All-Star for stock picking in Health Equipment & Supplies. Prior to becoming a Wall Street analyst, he served with Abbott Laboratories as a Project Manager in the Hospital Products Division, and as a Market Planner in the Abbott Diagnostics Division. Bruce began his Wall Street career at Vector Securities and has held senior analyst positions at Wachovia, RBC, Morgan Joseph TriArtisan, and Northland Securities. Bruce received a BA degree from University of Wisconsin and an MBA in General Management from the Johnson Graduate School of Management at Cornell University.
Lake Street Link: http://www.lakestreetcapitalmarkets.com/Approach/Lake-Street-Team/36
New CYTR Positive Forbes Article Out: The Race To Develop A Brain Cancer Treatment Takes An Interesting Turn
http://www.forbes.com/sites/tommeyer/2013/12/27/the-race-to-develop-a-brain-cancer-treatment-takes-an-interesting-turn/
150,000 Premarket Order placed
Pre-Market Time (ET): 08:21
Pre-Market Price $.4261
Pre-Market Volume: 150,000
Read more: http://www.nasdaq.com/symbol/mstx/premarket#ixzz2oOu9lKiC
Source: Reuters
Link: http://www.reuters.com/article/2012/04/17/idUS217635+17-Apr-2012+BW20120417
LAVIV™ (azficel-T) Pivotal Trial Data Published in Peer-Reviewed Journal, Dermatologic Surgery
-Data Shows Statistically Significant Improvement in Appearance of “Smile Line” Wrinkles-
-------------------------------
An excerpt from the above:
This analysis combined results from two studies and required a 2-point improvement in both patient and investigator wrinkle assessments. Based on this standard, 30% of subjects who received at least one LAVIV injection had a 2-point improvement in the appearance of smile lines six months after completing treatment, as rated by investigators, versus 8% for placebo.
In self-assessments, 59% of patients reported a two-point improvement six months after completing treatment, versus 26% for placebo. See the full prescribing information for LAVIV for results from the each of the two individual studies including the adverse reactions reported in = 1% of subjects. The safety and efficacy of LAVIV for areas other than the nasolabial folds have not been established.
Every company tries to spin their data and wow investors with stats. You think GM isn't going to promote the fact that they have X number of people who have signed up to drive (or are driving) the Volt?
The fact of the matter is, doctors should be trained to administer any medicine or undertake any procedure correctly. It's the first step. If they didn't promote the fact that X number of docs have been trained to date, then I'm sure there'd be people out there knocking them for that too.
Whether or not LaViv takes off is anybody's guess. But to simply dismiss the fact that they have interest in their product and are training doctors who will never ever use their product is silly.
Exactly. Doctors like to avoid their practice and their paying patients as much as they can and sneak out to be trained in new procedures that they'll never use (and play donkey kong too at the arcade). It's genius. It's kinda like when I spend every weekend at a timeshare presentation just so I can get the lil hot dog hors d'oeuvres, the free pen, and see the red-faced look of anger on the salesperson when they shove me out the back door.
Dr. McDanie's site highlighting LaViv and his appearances on WVEC.com talking about LaViv.
link: http://www.drmcdaniel.com/our-services/fibrocell-laviv
Link: http://www.prnewswire.com/news-releases/newest-breakthrough-all-natural-filler-now-available-in-new-york-with-dr-michelle-yagoda-139441063.html
NEW YORK, Feb. 16, 2012 /PRNewswire/ -- Dr. Michelle Yagoda, an esteemed NYC facial plastic surgeon, is pleased to announce the arrival of LaViv (Fibrocell Science, Exton, PA), an all-natural injectable filler made from one's very own collagen-producing cells, to her practice (www.DrYagoda.com) of facial plastic surgery and integrative aesthetics.
LaViv is a breakthrough for those who prefer fillers made of natural materials. It uses absolutely no synthetic materials—just one's own collagen-producing cells! FDA-approved for reducing lines and wrinkles, and for restoring volume, LaViv is a welcome addition to Dr. Yagoda's integrative aesthetic and facial plastic surgery practice where she already offers a wide range of anti-aging and volumizing therapies.
Dr. Yagoda's web site and info: http://www.dryagoda.com/
Affiliated with New York's finest hospitals, Dr. Yagoda is an assistant adjunct attending physician and clinical instructor at Manhattan Eye, Ear and Throat Hospital, Lenox Hill Hospital and The New York Eye and Ear Infirmary. Her private office with operating suite is located steps away from the Metropolitan Museum of Art on Fifth Avenue on Manhattan's prestigious Upper East Side. Dr. Yagoda caters to selective, professional and celebrity clientele. She is thorough, compassionate, discreet and widely regarded as an excellent teacher and surgeon.
Her press page is loaded with TV, print and other media. A lot of appearances on Fox & Friends.
Media link: http://www.dryagoda.com/media.html
http://www.hotstocked.com/8-k/fibrocell-science-inc-FCSC-1166951.html
December 13, 2011
Fibrocell Science, Inc. (“Company”) was advised by the FDA that it was unable to grant the Company’s request for orphan-drug designation for azficel-T for the repair of post burn contracture scars where surgery has failed, is contraindicated, or when donor sites for repair are not sufficient or desirable due to the physiological condition of the patient, based on the Company’s application dated August 30, 2011.
The ability to receive orphan-drug designation requires that population estimate for the designation is less than 200,000 in the U.S. Since the data presented to the FDA indicated that azficel-T can repair many kinds of dermal and subcutaneous defects, the FDA stated that the target population of azficel-T includes patients with wounds, scars and contractures induced by many sources.
As such, the Company was unable to provide an accurate population estimate, was unable to provide evidence that the prevalence is less than 200,000, and did not provide a plausible rationale for limiting the use of azficel-T to those patients in the proposed indication.
Fibrocell Science, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
http://www.businesswire.com/news/home/20111201005366/en/Fibrocell-Science-Present-Oppenheimer-22nd-Annual-Healthcare
Oppenheimer Healthcare Conference 2011
EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company’s Chairman and CEO, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference to be held on December 13-14, 2011 at the Waldorf=Astoria in New York City.
Fibrocell’s presentation is scheduled for Wednesday, December 14, 2011 at 11:25 AM Eastern Time.
The presentation will be webcast live, and a replay will be available on the Investors section of the Company's website at www.fibrocellscience.com.
Studies Back Azficel-T for Nasolabial Fold Wrinkles
Skin & Allergy News
12/7/11
http://www.skinandallergynews.com/news/aesthetic-dermatology/single-article/studies-back-azficel-t-for-nasolabial-fold-wrinkles/0bd231e371.html
Baltimore Sun
December 4, 2011
Reuters
Factbox: Stem cell advances focus on heart, inflammation
http://www.baltimoresun.com/health/sns-rt-us-stemcells-fbtre7b30fq-20111204,0,4022984.story
Fibrocell Science Inc, a company that is traded over the counter, received U.S. approval earlier this year for Laviv, its stem cell-based treatment for smile wrinkles. The product is made by extracting and multiplying a person's own collagen-making cells, and injecting them at the wrinkle site.
-------------------------
Article is a listing of Stem Cell companies of interest in the future.
Videos that Mr. Pernock has made with Film Annex. There are two from what I can gather, and are about 1 minute in length each.
About Fibroblast: http://www.filmannex.com/movie/ceo-david-pernock-of-fibrocell-science-inc-otcbb-fcsc-on-film-annex/29253
About FDA Approval: http://www.filmannex.com/movie/ceo-david-pernock-of-fibrocell-science-inc-otcbb-fcsc-on-lavivs-fda-approval/29252
I am not familiar with Film Annex, their posted profile states...
"Film Annex came to life with the goal to give filmmakers, artists, and content creators a free platform for self-distribution, interaction, and funding. We built an ad-supported video platform to enable content creators to monetize their content. This way, we encourage them to keep creating, contributing, educating, and of course, entertaining non-stop."
Technically, there's one more video, but its one that Mr. Pernock made to promote film annex.
http://www.filmannex.com/movie/ceo-david-pernock-of-fibrocell-science-inc-otcbb-fcsc-on-film-annex/29253
I believe there's some new pages on the web site detailing the process. I don't remember it there before and my internet crawler's alert sent it to me:
In the menu of the site are:
(Your Skin) http://www.mylaviv.com/your-skin.aspx
(Your LaViv) 3 part section, starting with:
http://www.mylaviv.com/smile-line-treatment.aspx
----------
I think its new but not sure.
Hiding Those Smile Lines
Indianapolis Star
November 13, 2011
http://www.indystar.com/article/20111113/LIVING25/111130317/
There's been a lot of talk about using stem cell therapy to cure many diseases. But it hasn't become reality in most cases.
One exception has come in the world of cosmetic medicine. LaViv, approved in July for the treatment of smile lines, uses a patient's own stem cells. Dr. Greg Chernoff, with Chernoff Cosmetic Surgery in Indianapolis, participated in the LaViv trials about a decade ago. Now he can offer this to all patients.
Follow link for the Q&A part of the story...
http://www.indystar.com/article/20111113/LIVING25/111130317/
MSNBC & Today Health picking up on the Miami NBC story:
http://today.msnbc.msn.com/id/45229370/ns/today-today_health/#.Trv_2vQr27s
I don't watch the national news programs, so I have no idea if it was mentioned on the Today show, or if its only the today show health online that was highlighting LaViv.
NBC Miami video and story highlighting LaViv and the procedure:
http://www.nbcmiami.com/news/local/New-Facial-Filler-now-available-in-Miami-133393038.html
8 girlfriends last night? Can I borrow a few?
I just noticed that there's also a web site that Fibrocell built that is for Healthcare Professionals. There's a link to it via their www.mylaviv.com web site (upper right corner).
I'm not sure if the new site for US Healthcare Professionals went up at the same time as the new main site, or if I just missed it at that time.
In any case, its at: http://www.lavivpro.com
word up
They have updated and put up a NEW http://www.mylaviv.com web site.
I have received about 15 notices via google alerts in the past day about the Allure Award being mentioned.
A short mention in the Philly Biz Journal. Includes a big photo of Mr. Pernock's head.
-------------------------------
http://www.bizjournals.com/philadelphia/print-edition/2011/09/09/fibrocell-irons-out-strategy-for.html
EXTON — Fibrocell Science Inc. is launching its regenerative cell therapy wrinkle treatment this month in Philadelphia and a half dozen other key markets around the country.
In addition to here, the Chester County biotechnology company plans to market laViv in Southern California, Atlanta, New York, Dallas, South Florida, and Washington, D.C.
“Our goal is to build long-term relationships with our physicians and our patients,” said David Pernock, Fibrocell’s CEO. “We believe it’s better to do things the right way, rather than doing things fast.”
Pernock declined to disclosed more details about the rollout for LaViv citing competitive reasons. Fibrocell ...
http://assets.bizjournals.com/philadelphia/print-edition/9-9%20David%20Pernock.jpg?v=1
The burn photos and information were indeed stunning. I can only imagine how anyone with a burn injury such as that would see this that kind of transformation as a life changing event. If I understood it correctly, not only did it change the appearance but the flexibility of the hand as well, as the person was then able to clench their fist. Maybe they would have anyway over time, or maybe it helped. Only they know. I don't see that I'll ever have any use for the beauty side of their product, but tragedy has no prejudice and one never knows what health issues that one might face in life.
There was a lot more in the presentation that i didn't get to delve into, as you mentioned, and more info on the acne scaring, and the future looking conceptions of replacing stem cells in certain uses (the partnership with UCLA).
There's a lot of neat concepts behind this. Whether or not it'll take off and in what capacity will be the key. Some things are ahead of their time (look at the segway, which only ended up finding a small niche at the moment, and the initial tablet computers that didn't take hold for years until apple transformed them). Sometimes it takes a few years to figure out new technologies. I'll give them a chance at least. GLTA. I hope they can help people.
As per today's investor conference weblink:
http://www.wsw.com/webcast/kbro23/fcsc/
A few notes ...
At approx: 6:20 into the presentation, Mr. Pernock states, (bring up slide 8), "...this is an example of what our advertising will look like... launching later on this month"
also...
Fibrocell was nominated for "beauty breakthrough of the year award" by Allure magazine, will know if they won it, sometime next week.
...skipping around ...he mentioned application for the "upper chest wall a few times throughout" which was new to me, whatever that specifically means. I'm not sure i've ever paid much attention to an upper chest wall, besides cleavage.
...Several scientific publications by the end of THIS year.
Also, at the end (slide 44), he states that launch is expected in China in 2012, but was mostly generalities about it, nothing specific that i heard.
that's was my compressed fast-forward version of things, FWIW.
Fibrocell Science, Inc. filed an S-1 statement (IPO Registration) on September 2, 2011 with the U.S. Securities and Exchange Commission. The S-1 filing can be viewed in its entirety by clicking here:
Source: http://marketbrief.com/fibrocell-science-inc/s1/ipo-registration/2011/9/2/9009359/filing
EXTON, Pa., Aug 25, 2011 (BUSINESS WIRE) -- Fibrocell Science, Inc. FCSC +7.32% , a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, the Company's Chairman and CEO, will be presenting at the Kaufman Bros. 14th Annual Investor Conference to be held on September 7-8, 2011 at the W Hotel New York.
Fibrocell's presentation is scheduled for Wednesday, September 7, at 12:00 p.m. Eastern Time.
The presentation will be webcast live, and a replay will be available on the Investors section of the Company's website at www.fibrocellscience.com.
link: http://www.marketwatch.com/story/fibrocell-science-inc-to-present-at-the-kaufman-bros-14th-annual-investor-conference-2011-08-25?reflink=MW_news_stmp
To add to your note, he said training was *not* difficult.
Good re-cap
I have to admit, their product works very well. I lost my smile lines after listening to that :(
Nothing earth-shattering either way I guess. One just figured that they would go a little bit into detail instead of saying what most investors already know.
I'm still long, and know as much as I did yesterday. As a Cubs fan, I'm used to being patient, and losing. Hmmmmmmm.
For those that weren't able to listen to the conference call, a recap can be found here:
From Shawshank Redemption...about Hope:
Red: Let me tell you something my friend. Hope is a dangerous thing. Hope can drive a man insane.
Andy: [in letter to Red] Remember Red, hope is a good thing, maybe the best of things, and no good thing ever dies.
------------------
In the end, Red leans Andy's way, so maybe there is Hope.
http://www.prweb.com/releases/2011/8/prweb8730787.htm
Link above is a PR From the Maryland Laser Skin and Vein Institute promoting Dr. Weiss and laViv. At least they are putting out a PR of some sort.
----------------------------------
It contains this snippet, for what its worth:
"Additional information about laVív, including complete Prescribing Information, will be available on http://www.mylaviv.com within the coming days."
link: http://www.prweb.com/releases/2011/8/prweb8730787.htm
Thank you. I found that simple to understand and informative. Much appreciated (from a board lurker).
A sample note from a physician from Indianapolis, who has used the process in the past:
http://exploreplasticsurgery.com/tag/fibrocell/
...While the FDA approval for this technology is recent, it is a older technique that was initially introduced over a decade ago. At that time, it was offered as a physician-ordered treatment that did not have FDA-approved status. I did several patients at that time and was using it in the treatment of depressed facial scars, specifically acne scars. It was my understanding that the company eventually decided to seek FDA approval for fear that growing and storing human cells would eventually come under the scrutiny of the FDA. This is now the fruit of a long effort at going through the FDA submission process.
(more at above link)
Off Label Purposes - Waaaaay Off
My friend wants to know if perhaps the Fibrocell system could be used - for other purposes - besides wrinkles, you know, like in the Netherlands Region.
My friend wonders if maybe injections would, *ahem*, increase the size of the overall area.
My friend is shy, has a spotty internet connection, and/or doesn't speak the English, so I'm asking on his behalf.
Since Botox relaxes muscles, I'm not sure that it would be good to use in that specific area.
He was just wondering. Thanks.
Skin and Allergy News Publication
http://www.skinandallergynews.com/news/aesthetic-dermatology/single-article/newly-approved-filler-uses-patient-s-own-cells/1ef9a5228e.html
------------------------
Skin & Allergy News Digital Network is the online destination and multimedia properties of Skin & Allergy News, the independent news publication for the dermatology community. Since 1970, Skin & Allergy News has been the leading source of news and commentary about clinical developments in dermatology as well as health care policy and regulations that affect the physician’s practice. Skin & Allergy News Digital Network is owned by the International Medical News Group division of Elsevier.
Nothing came up in a search of the ET Online site, however if one wishes to find when its on, in your area,
http://www.etonline.com/
and then scroll to the bottom of the site and there's a "Show Finder" section to enter your zip code. Selena Gomez and Cars 2 will also be featured :)